A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Registrational; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 11 Sep 2017 Planned End Date changed from 4 Dec 2019 to 11 Dec 2019.
- 06 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 4 Jul 2018.
- 06 Feb 2017 Status changed from not yet recruiting to recruiting.